Prasco Laboratories announced that it has entered into agreements with Teva Pharmaceutical Industries Ltd. (Teva) and Shire LLC, an indirect subsidiary of Shire plc, to acquire the rights to distribute Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate (Mixed Salts of a Single-Entity Amphetamine Product) Extended Release Capsules, CII, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg, the Authorized Generic (AG) version of Adderall XR® Extended Release Capsules, CII. As a result of this acquisition, Prasco will market an AG version of Adderall XR Capsules, CII in the United States that is therapeutically equivalent and substitutable for prescriptions written for Adderall XR, a CNS stimulant that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
The Authorized Generic of Adderall XR is being divested by Teva as a precondition to its pending acquisition of Allergan’s generics business. Upon closing of its transaction with Teva, Prasco will immediately take over the distribution of the product, providing a seamless transition for both customers and patients.
“We are pleased to offer consumers an Authorized Generic of Adderall XR, thus allowing physicians, pharmacists, and consumers to experience product continuity between the brand and Prasco’s therapeutically-equivalent AG version of Adderall XR,” said Prasco chief executive officer, Chris Arington.
“Prasco continually looks for opportunities to expand its product portfolio, and this agreement represents our strategy of growth through acquisition,” stated Jonathan Lapps, Prasco senior vice president of business development. “Our existing business platform and successful experience with more than 40 brand company partners speaks to Prasco’s prominence as the premier AG partner.”
As the leader in the Authorized Generics business, Prasco has now brought more than 75 AG products to market since 2004 and has more AG partners than any other company in the U.S. Authorized Generic products can benefit multiple members of the marketplace by helping enhance access to treatment options.
Source : prasco.com